Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The predictive utility of placental growth factor testing between 26 and 28 weeks in screening for preterm delivery due to placenta-mediated complications: A prospective cohort study in 5,000 apparently low-risk pregnancies

FY 2022-23

Summary
Pre-eclampsia is a potentially life-threatening pregnancy complication, causing elevated blood pressure with injury to important organs. It is strongly associated with abnormal development of and progressive damage to the placenta. There is no cure for the disease, other than removal of the diseased placenta, which results in premature delivery of the fetus. Placental growth factor (PlGF) is a protein released by the placenta, causing relaxation of the mother’s blood vessels, thereby preventing high blood pressure as blood volume increases in normal pregnancy. When the placenta does not form properly, as in pre-eclampsia, PlGF fails to rise appropriately. Maternal blood vessels progressively tighten, causing high blood pressure and organ damage. PlGF has been shown to be a strong predictor for short-term development of pre-eclampsia; a normal PlGF value effectively excludes the disease. Despite this, PlGF has not been thoroughly evaluated in routine obstetrical care. Our study aims to assess if a PlGF blood test between 26 and 28 weeks of pregnancy can predict the risk of preterm birth before 34+0 weeks among apparently healthy pregnancies. Women with twins or triplets, or with high-risk pregnancies will be excluded. So far, we have recruited over 4,000 women to this ongoing cohort. We expect to reach our target sample size of 5,000 by February 2023. This project will be one of the largest observational studies evaluating the screening accuracy of PlGF testing in low-risk pregnant people. If we find a significant difference in the rate of preterm delivery at less than 34+0 weeks between the low PlGF and the normal PlGF groups, the test could potentially be incorporated more widely to tailor pregnancy care and improve outcomes for mothers and babies worldwide.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486451
Name
Gladstone Rachel A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The predictive utility of placental growth factor testing between 26 and 28 weeks in screening for preterm delivery due to placenta-mediated complications: A prospective cohort study in 5,000 apparently low-risk pregnancies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Hypertension; Placental Growth Factor; Pre-Eclampsia; Pregnancy; Prevention
Abstract
Pre-eclampsia is a potentially life-threatening pregnancy complication, causing elevated blood pressure with injury to important organs. It is strongly associated with abnormal development of and progressive damage to the placenta. There is no cure for the disease, other than removal of the diseased placenta, which results in premature delivery of the fetus. Placental growth factor (PlGF) is a protein released by the placenta, causing relaxation of the mother’s blood vessels, thereby preventing high blood pressure as blood volume increases in normal pregnancy. When the placenta does not form properly, as in pre-eclampsia, PlGF fails to rise appropriately. Maternal blood vessels progressively tighten, causing high blood pressure and organ damage. PlGF has been shown to be a strong predictor for short-term development of pre-eclampsia; a normal PlGF value effectively excludes the disease. Despite this, PlGF has not been thoroughly evaluated in routine obstetrical care. Our study aims to assess if a PlGF blood test between 26 and 28 weeks of pregnancy can predict the risk of preterm birth before 34+0 weeks among apparently healthy pregnancies. Women with twins or triplets, or with high-risk pregnancies will be excluded. So far, we have recruited over 4,000 women to this ongoing cohort. We expect to reach our target sample size of 5,000 by February 2023. This project will be one of the largest observational studies evaluating the screening accuracy of PlGF testing in low-risk pregnant people. If we find a significant difference in the rate of preterm delivery at less than 34+0 weeks between the low PlGF and the normal PlGF groups, the test could potentially be incorporated more widely to tailor pregnancy care and improve outcomes for mothers and babies worldwide.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gladstone, Rachel A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~